Literature DB >> 21606885

Relationship between clinicopathological factors and fluorine-18-fluorodeoxyglucose uptake in patients with papillary thyroid cancer.

Hayato Kaida1, Yuji Hiromatsu, Seiji Kurata, Akihiko Kawahara, Satoshi Hattori, Tomoki Taira, Maiko Kobayashi, Masafumi Uchida, Kentaro Yamada, Hiroyuki Mihashi, Hirohito Umeno, Masayoshi Kage, Tadashi Nakashima, Naofumi Hayabuchi, Masatoshi Ishibashi.   

Abstract

OBJECTIVE: To examine the relationship between clinicopathological factors and fluorine-18-fluorodeoxyglucose (F-FDG) uptake in patients with papillary thyroid cancer (PTC).
MATERIALS AND METHODS: Fifty-four patients were included in this study.F-FDG positron emission tomography was performed before surgery. Immunohistochemistry of glucose transporter (GLUT) was performed using postoperative histopathological specimens. We investigated the relationship between maximum standardized uptake value (SUVmax) and GLUT-1, GLUT-3, and GLUT-4 expression/SUVmax and prognostic risk factors {tumor size, age, sex, extrathyroidal extension, and lymph node metastasis [ly (+)]}.
RESULTS: GLUT-3 and GLUT-4 expressions significantly correlated with SUVmax (GLUT-3: r=0.38, P=0.008; GLUT-4: r=0.46, P=0.001), but GLUT-1 did not (r=0.21, P=0.147). The tumor size correlated with SUVmax (r=0.5, P<0.001), but GLUT-1, GLUT-3, and GLUT-4 did not (GLUT-1: r=0.006, P=0.681; GLUT-3: r=0.05, P=0.705; GLUT-4: r=-0.17, P=0.217). Both SUVmax and GLUT-4 expressions were statistically significant with ly (+) (SUVmax: P=0.012; GLUT-4: P=0.018), but GLUT-1 and GLUT-3 expressions were not (GLUT-1: P=0.165; GLUT-3: P=0.499). There was no significant difference between other clinicopathological factors and SUVmax or any GLUT expressions.
CONCLUSION: F-FDG uptake in PTC may be determined by GLUT-3 and GLUT-4 expressions and may be related to tumor size and lymph node metastasis of PTC. F-FDG uptake may reflect tumor progression of PTC.
Copyright © 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21606885     DOI: 10.1097/MNM.0b013e32834754f1

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  13 in total

1.  ¹⁸F-FDG uptake as a prognostic variable in primary differentiated thyroid cancer incidentally detected by PET/CT: a multicentre study.

Authors:  Arnoldo Piccardo; Matteo Puntoni; Francesco Bertagna; Giorgio Treglia; Luca Foppiani; Federico Arecco; Raffaele Giubbini; Mehrdad Naseri; Angelina Cistaro; Manlio Cabria; Francesca Bardesono; Luca Ceriani; Fabio Orlandi; Luca Giovanella
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-04-30       Impact factor: 9.236

2.  [18F]FDG Uptake and Expression of Immunohistochemical Markers Related to Glycolysis, Hypoxia, and Proliferation in Indeterminate Thyroid Nodules.

Authors:  Elizabeth J de Koster; Adriana C H van Engen-van Grunsven; Johan Bussink; Cathelijne Frielink; Lioe-Fee de Geus-Oei; Benno Kusters; Hans Peters; Wim J G Oyen; Dennis Vriens
Journal:  Mol Imaging Biol       Date:  2022-10-17       Impact factor: 3.484

3.  Correlation of BRAF mutation and SUVmax levels in thyroid cancer patients incidentally detected in 18F-fluorodeoxyglucose positron emission tomography.

Authors:  Aysenur Ozderya; Sule Temizkan; Aylin Ege Gul; Sule Ozugur; Mehmet Sargin; Kadriye Aydin
Journal:  Endocrine       Date:  2016-10-01       Impact factor: 3.633

4.  Association Between (18)F-FDG Avidity and the BRAF Mutation in Papillary Thyroid Carcinoma.

Authors:  Suk Hyun Lee; Sangwon Han; Hyo Sang Lee; Sun Young Chae; Jong Jin Lee; Dong Eun Song; Jin-Sook Ryu
Journal:  Nucl Med Mol Imaging       Date:  2015-09-22

5.  Clinicopathologic characteristics of synchronous primary thyroid cancer detected by initial staging 18F-FDG PET-CT examination in patients with underlying malignancy.

Authors:  Bo Hyun Kim; Chang Hun Lee; Seong-Jang Kim; Yun Kyung Jeon; Sang Soo Kim; Yong Ki Kim; In Ju Kim
Journal:  Thyroid       Date:  2013-07-25       Impact factor: 6.568

6.  Gene and protein expression of glucose transporter 1 and glucose transporter 3 in human laryngeal cancer-the relationship with regulatory hypoxia-inducible factor-1α expression, tumor invasiveness, and patient prognosis.

Authors:  Katarzyna Starska; Ewa Forma; Paweł Jóźwiak; Magdalena Bryś; Iwona Lewy-Trenda; Ewa Brzezińska-Błaszczyk; Anna Krześlak
Journal:  Tumour Biol       Date:  2014-11-21

7.  Correlation of pretreatment 18F-FDG uptake with clinicopathological factors and prognosis in patients with newly diagnosed diffuse large B-cell lymphoma.

Authors:  Honghui Huang; Fei Xiao; Xiaofeng Han; Lu Zhong; Hua Zhong; Lan Xu; Jianyi Zhu; Beiwen Ni; Jia Liu; Yi Fang; Minyue Zhang; Lijing Shen; Ting Wang; Jianjun Liu; Yiping Shi; Yumei Chen; Luying Zheng; Qiang Liu; Fangyuan Chen; Jianmin Wang
Journal:  Nucl Med Commun       Date:  2016-07       Impact factor: 1.690

8.  Expression of Glut-1 and HK-II in Pancreatic Cancer and Their Impact on Prognosis and FDG Accumulation.

Authors:  Hai-Jing Yang; Wei-Jia Xu; Yi-Hui Guan; Hui-Wei Zhang; Wei-Qun Ding; Lan Rong; Zhi-Bing Qiu; Liang Zhong
Journal:  Transl Oncol       Date:  2016-12       Impact factor: 4.243

9.  Associations between GLUT expression and SUV values derived from FDG-PET in different tumors-A systematic review and meta analysis.

Authors:  Hans-Jonas Meyer; Andreas Wienke; Alexey Surov
Journal:  PLoS One       Date:  2019-06-17       Impact factor: 3.240

10.  Relation Between F-18 FDG Uptake of PET/CT and BRAFV600E Mutation in Papillary Thyroid Cancer.

Authors:  Seokho Yoon; Young-Sil An; Su Jin Lee; Eu Young So; Jang-Hee Kim; Yoon-Sok Chung; Joon-Kee Yoon
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.